Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 7 |
| List of Tables | 8 | 3 |
| List of Figures | 11 | 1 |
| Immunoglobulins Market to 2019 - Introduction | 12 | 1 |
| Overview | 12 | 1 |
| Immunoglobulins Market to 2019 - Market Overview | 13 | 4 |
| Revenue | 13 | 1 |
| Annual Cost of Therapy | 14 | 1 |
| Immunoglobulins Market Drivers and Restraints | 15 | 1 |
| Market Drivers | 15 | 1 |
| Immunology Neurological Conditions and Hematology to Continue to Dominate the Market | 15 | 1 |
| Approval and Positive Reception for Subcutaneous Immunoglobulin Expected to Contribute to a Slight Increase in the Growth Rate | 15 | 1 |
| Continued R&D Interest and Investment in Immunoglobulin for the Treatment of Alzheimer s Disease | 15 | 1 |
| Restraints | 16 | 1 |
| Supply Shortages and High Production Costs Due to Reliance on Plasma Collection and Fractionation | 16 | 1 |
| Weak Pipeline and Lack of Product Approvals | 16 | 1 |
| Immunoglobulins Market to 2019 - Geographical Landscape | 17 | 8 |
| US | 17 | 1 |
| Revenue | 17 | 2 |
| Annual Cost of Therapy | 19 | 1 |
| Top Five European Countries | 20 | 1 |
| Revenue | 20 | 2 |
| Annual Cost of Therapy | 22 | 1 |
| Japan | 23 | 1 |
| Revenue | 23 | 1 |
| Annual Cost of Therapy | 24 | 1 |
| Immunoglobulins Market to 2019 - Therapeutic Landscape | 25 | 54 |
| Main Therapeutic Indications | 25 | 1 |
| Indicated Conditions for Intravenous Immunoglobulin Usage - US | 25 | 1 |
| Indications for Intravenous Immunoglobulin Usage - Europe | 25 | 1 |
| Guidelines for Intravenous Immunoglobulin Usage - UK | 26 | 1 |
| Indications for Intravenous Immunoglobulin Usage - Japan | 26 | 1 |
| Revenue Share for the Major Therapeutic Indications | 27 | 1 |
| Primary Immunodeficiency Market | 28 | 1 |
| Introduction | 28 | 1 |
| Revenue | 29 | 2 |
| Annual Cost of Therapy | 31 | 2 |
| Epidemiology | 33 | 1 |
| Prevalence Population | 33 | 1 |
| Diagnosed Population | 33 | 1 |
| Treatment Population | 34 | 1 |
| Current Use | 35 | 1 |
| Current Immunoglobulin Uses | 35 | 1 |
| Current Use for Other Therapies | 35 | 1 |
| Geographical Segmentation | 36 | 1 |
| Guillain-Barr Syndrome Market | 37 | 1 |
| Introduction | 37 | 1 |
| Revenue | 38 | 1 |
| Annual Cost of Therapy | 39 | 1 |
| Epidemiology | 40 | 1 |
| Incidence Population | 40 | 1 |
| Diagnosed Population | 40 | 1 |
| Treatment Population | 41 | 1 |
| Current Use for Therapies | 41 | 1 |
| Current Immunoglobulin Use | 41 | 1 |
| Current Use for Other Therapies | 41 | 1 |
| Geographical Segmentation | 42 | 2 |
| Chronic Lymphocytic Leukemia Market | 44 | 1 |
| Introduction | 44 | 1 |
| Revenue | 45 | 1 |
| Annual Cost of Therapy | 46 | 1 |
| Epidemiology | 47 | 1 |
| Prelevance Population | 47 | 1 |
| Diagnosed Population | 47 | 1 |
| Treatment Population | 47 | 1 |
| Current Use | 48 | 1 |
| Current Immunoglobulin Use | 48 | 1 |
| Current Use for Other Therapies | 48 | 1 |
| Geographical Segmentation | 49 | 2 |
| Chronic Inflammatory Demyelinating Polyneuropathy Market | 51 | 1 |
| Introduction | 51 | 1 |
| Revenue | 52 | 1 |
| Annual Cost of Therapy | 53 | 1 |
| Epidemiology | 54 | 1 |
| Prevalence Population | 54 | 1 |
| Diagnosed Population | 54 | 1 |
| Treatment Population | 54 | 1 |
| Current Use | 55 | 1 |
| Current Immunoglobulin Use | 55 | 1 |
| Current Use for Other Therapies | 55 | 1 |
| Geographical Segmentation | 56 | 2 |
| Myasthenia Gravis Market | 58 | 1 |
| Introduction | 58 | 1 |
| Revenue | 59 | 1 |
| Annual Cost of Therapy | 60 | 1 |
| Epidemiology | 61 | 1 |
| Prevalence Population | 61 | 1 |
| Diagnosed Population | 61 | 1 |
| Treatment Population | 61 | 1 |
| Current Use | 62 | 1 |
| Current Immunoglobulin Use | 62 | 1 |
| Current Use for Other Therapies | 62 | 1 |
| Geographical Segmentation | 63 | 2 |
| Multifocal Motor Neuropathy Market | 65 | 1 |
| Introduction | 65 | 1 |
| Revenue | 66 | 1 |
| Annual Cost of Therapy | 67 | 1 |
| Epidemiology | 68 | 1 |
| Prevalence Population | 68 | 1 |
| Diagnosed Population | 68 | 1 |
| Treatment Population | 68 | 1 |
| Current Use | 69 | 1 |
| Current Immunoglobulin Use | 69 | 1 |
| Current Use for Other Therapies | 69 | 1 |
| Geographical Segmentation | 70 | 2 |
| Idiopathic Thrombocytopenic Purpura | 72 | 1 |
| Introduction | 72 | 1 |
| Revenue | 73 | 1 |
| Annual Cost of Therapy | 74 | 1 |
| Epidemiology | 75 | 1 |
| Prevalence Population | 75 | 1 |
| Diagnosed Population | 75 | 1 |
| Treatment Population | 75 | 1 |
| Current Use | 76 | 1 |
| Current Immunoglobulin Use | 76 | 1 |
| Current Use for Other Therapies | 76 | 1 |
| Geographical Segmentation | 77 | 2 |
| Immunoglobulins Market to 2019 - Profiles of Marketed Products | 79 | 16 |
| Overview | 79 | 2 |
| Privigen | 81 | 1 |
| Overview | 81 | 1 |
| Approved Indications | 81 | 1 |
| Safety | 81 | 1 |
| Efficacy | 82 | 1 |
| Primary Humoral Immunodeficiency | 82 | 1 |
| Immune Thrombocytopenic Purpura | 82 | 1 |
| Guillain-Barr Syndrome | 82 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy | 82 | 1 |
| Gammagard S/D | 83 | 1 |
| Overview | 83 | 1 |
| Approved Indications | 83 | 1 |
| Safety | 83 | 1 |
| Efficacy | 84 | 1 |
| Primary Immunodeficiency Diseases | 84 | 1 |
| Chronic Lymphocytic Leukemia | 84 | 1 |
| Idiopathic Thrombocytopenic Purpura | 84 | 1 |
| Gammagard Liquid | 85 | 1 |
| Overview | 85 | 1 |
| Approved Indications | 85 | 1 |
| Safety | 85 | 1 |
| Efficacy | 86 | 1 |
| Primary Immunodeficiency | 86 | 1 |
| Multifactor Motor Neuropathy | 86 | 1 |
| Octagam 5% | 87 | 1 |
| Overview | 87 | 1 |
| Approved Indications | 87 | 1 |
| Safety | 87 | 1 |
| Efficacy | 88 | 1 |
| Flebogamma 10% DIF | 88 | 1 |
| Overview | 88 | 1 |
| Approved Indications | 88 | 1 |
| Safety | 88 | 1 |
| Efficacy | 88 | 1 |
| Gamunex-C | 89 | 1 |
| Overview | 89 | 1 |
| Approved Indications | 89 | 1 |
| Safety | 89 | 1 |
| Primary Immunodeficiency Diseases | 89 | 1 |
| Idiopathic Thrombocytopenic Purpura | 89 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy | 89 | 1 |
| Efficacy | 90 | 1 |
| Primary Humoral Immunodeficiency by the Intravenous Route | 90 | 1 |
| Idiopathic Thrombocytopenic Purpura | 90 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy | 90 | 1 |
| Gammaplex | 91 | 1 |
| Overview | 91 | 1 |
| Approved Indications | 91 | 1 |
| Safety | 91 | 1 |
| Efficacy | 92 | 1 |
| Primary Immunodeficiency Diseases | 92 | 1 |
| Idiopathic Thrombocytopenic Purpura | 92 | 1 |
| HyQvia | 93 | 1 |
| Overview | 93 | 1 |
| Approved Indications | 93 | 1 |
| Safety | 93 | 1 |
| Efficacy | 93 | 1 |
| Bivigam | 94 | 1 |
| Overview | 94 | 1 |
| Approved Indications | 94 | 1 |
| Safety | 94 | 1 |
| Efficacy | 94 | 1 |
| Immunoglobulins Market to 2019 - Pipeline Analysis | 95 | 4 |
| Research and Development Pipeline | 95 | 2 |
| Major Pipeline Product Profiles | 97 | 1 |
| IVIG3I Grifols 10% | 97 | 1 |
| Product Description | 97 | 1 |
| Mechanism of Action | 97 | 1 |
| Clinical Study Details | 97 | 1 |
| RI-002 (IVIG) | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| Clinical Study Details | 98 | 1 |
| Immunoglobulins Market to 2019 - Competitive Landscape | 99 | 8 |
| Baxter International Inc. | 99 | 1 |
| Business Description | 99 | 1 |
| Recent Developments | 100 | 1 |
| Biotest Pharmaceuticals | 101 | 1 |
| Business Description | 101 | 1 |
| Recent Developments | 101 | 1 |
| Bio Products Laboratory Ltd. | 102 | 1 |
| Business Description | 102 | 1 |
| Recent Developments | 102 | 1 |
| CSL Behring Limited | 103 | 1 |
| Business Description | 103 | 1 |
| Recent Developments | 103 | 1 |
| Grifols S.A. | 104 | 1 |
| Business Description | 104 | 1 |
| Recent Developments | 105 | 1 |
| Octapharma AG | 106 | 1 |
| Business Description | 106 | 1 |
| Recent Developments | 106 | 1 |
| Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape | 107 | 2 |
| M&A Deals | 107 | 1 |
| Grifols Buys 60% of Progenika Biopharma | 107 | 1 |
| Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience | 107 | 1 |
| Grifols Purchases Three Plasma Donation Centers in the US from Canada s Cangene | 107 | 1 |
| Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro | 107 | 1 |
| R&D Licensing Agreements | 108 | 1 |
| Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib | 108 | 1 |
| Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies | 108 | 1 |
| Baxter Announces 20 Year Partnership with Hemobras in Brazil | 108 | 1 |
| Immunoglobulins Market to 2019 - Asia-Pacific and China | 109 | 20 |
| India | 109 | 1 |
| Overview | 109 | 1 |
| Regulatory Landscape | 109 | 1 |
| National Institute for Biologicals | 110 | 1 |
| Marketed Products | 110 | 1 |
| Primary Immune Deficiency | 110 | 1 |
| Guillain-Barr Syndrome | 111 | 1 |
| Chronic Lymphocytic Leukemia | 111 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy | 111 | 1 |
| Idiopathic Thrombocytopenic Purpura | 112 | 1 |
| Product Profiles | 113 | 1 |
| Ivnex Safe | 113 | 1 |
| Aunativ | 113 | 1 |
| Verglob | 113 | 1 |
| Company Profiling | 114 | 1 |
| Biocon Limited | 114 | 1 |
| Reliance Life Sciences Pvt. Ltd. | 115 | 1 |
| Zydus Cadila Healthcare Limited | 116 | 1 |
| Sun Pharmaceutical Industries Inc. | 117 | 1 |
| China | 118 | 1 |
| Overview | 118 | 1 |
| Regulatory Information | 118 | 1 |
| Blood Products Industry Regulations | 118 | 2 |
| National Institute for Control for Pharmaceutical and Biological Products | 120 | 1 |
| Marketed Products | 120 | 1 |
| Gammaraas | 120 | 1 |
| Company Profiling | 121 | 1 |
| Shanghai RAAS Blood Products Co., Ltd. | 121 | 1 |